Improved Survival Rates in Skin Cancer Trial with Merck-Moderna Drug Combination
In a groundbreaking study, Moderna and Merck report positive results for their mRNA-4157 treatment combined with Keytruda in high-risk...
Revolutionize Your Finance News Experience with MorningExpert!
🌟 Custom-Tailored News Just for You: Say goodbye to information overload. Our cutting-edge filtering technology curates your feed to perfection, delivering only the finance news that matches your interests and professional ambitions.
🔔 Flexible Updates, Your Way: How do you like your updates? Choose from instant app notifications, email digests, or captivating video summaries to stay informed on your own terms.
🎥 Engaging Video Summaries: Pressed for time? Let our expert anchors brief you with video summaries, giving you the essence of each news piece in minutes.
🚨 Personalized Alerts: Never miss out on what matters most. Set custom alarms for topics you’re passionate about, and be the first in the know.
📹 Create Your Own Video Content: Dive deeper into the topics that intrigue you with personalized videos. Generated on demand, these videos bring your chosen keywords or interests to life.
MorningExpert is more than a news app; it’s a dedicated companion for anyone passionate about finance. Whether you’re a seasoned professional, an avid enthusiast, or simply eager to stay updated with the finance world, our app ensures you’re always ahead of the curve.
With features designed to make staying informed effortless and enjoyable—such as custom alarms and on-demand video content—navigating the finance landscape has never been simpler or more tailored to your needs.
Transform the way you consume finance news. Download MorningExpert now and step into a world of precision-informed finance knowledge. Your next-level finance journey starts here!
acquisition adjusted earnings AI analysts apple artificial intelligence Bitcoin CEO China demand dividend Donald Trump Dow Jones Industrial Average earnings economy extreme event FactSet Federal Reserve fourth quarter growth guidance hamas inflation interest rates investment investors Israel Microsoft net income net profit Nvidia profit revenue revenue growth S&P 500 sales shareholders shares stock stock market stocks tesla third quarter Trump Wall Street
In a groundbreaking study, Moderna and Merck report positive results for their mRNA-4157 treatment combined with Keytruda in high-risk...
Virios Therapeutics' shares plummeted 35% in extended trading after announcing a public offering to finance a long-Covid-19 study, following...
Sagimet Biosciences, a clinical-stage biopharmaceutical company, saw its stock more than double and reach an all-time high after reporting...
Shares of Sagimet Biosciences surged nearly 10% in premarket trading today after the company announced positive results from a...
Praxis Precision Medicines saw a 23% increase in shares, reaching $31, after providing an update on its portfolio. The...
Pulmatrix, a biopharmaceutical company, is closing a study on a potential treatment for a fungal lung infection in order...
Hepion Pharmaceuticals, a clinical-stage biopharmaceutical company, is cutting operating costs by 60% to preserve capital while exploring strategic and...
Pfizer's Phase 2b study of its obesity pill, danuglipron, has yielded mixed results. While the study showed a significant...
Shares of Aclaris Therapeutics plummeted over 85% in premarket trading today after the company's drug candidate, zunsemetinib, failed to...
Aclaris Therapeutics, a biopharmaceutical company, saw its shares plummet nearly 90% and hit an all-time low after abandoning its...